The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Eva Degerman

Eva Degerman

Research team manager

Eva Degerman

C(2)-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes.


  • Jie Mei
  • Lena Stenson
  • Tova Landström
  • Cecilia Holm
  • David Brindley
  • Vincent Manganiello
  • Eva Degerman

Summary, in English

Cyclic nucleotide phosphodiesterase (PDE) 3B plays an important role in the antilipolytic action of insulin and, thereby, the release of fatty acids from adipocytes. Increased concentrations of circulating fatty acids as a result of elevated or unrestrained lipolysis cause insulin resistance. The lipolytic action of tumor necrosis factor (TNF)-alpha is thought to be one of the mechanisms by which TNF-alpha induces insulin resistance. Ceramide is the suggested second messenger of TNF-alpha action, and in this study, we used 3T3-L1 adipocytes to investigate the effects of C(2)-ceramide (a short-chain ceramide analog) on the expression and regulation of PDE3B and lipolysis. Incubation of adipocytes with 100 micromol/l C(2)-ceramide (N-acetyl-sphingosine) resulted in a time-dependent decrease of PDE3B activity, accompanied by decreased PDE3B protein expression. C(2)-ceramide, in a time- and dose-dependent manner, stimulated lipolysis, an effect that was blocked by H-89, an inhibitor of protein kinase A. These ceramide effects were prevented by 20 micromol/l troglitazone, an antidiabetic drug. In addition to downregulation of PDE3B, the antilipolytic action of insulin was decreased by ceramide treatment. These results, together with data from other studies on PDE3B and lipolysis in diabetic humans and animals, suggest a novel pathway by which ceramide induces insulin resistance. Furthermore, PDE3B is demonstrated to be a target for troglitazone action in adipocytes.


  • Appetite Regulation
  • Insulin Signal Transduction
  • Department of Experimental Medical Science
  • Molecular Endocrinology

Publishing year












Document type

Journal article


American Diabetes Association Inc.


  • Endocrinology and Diabetes


  • Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors
  • Drug Interactions
  • Enzyme Inhibitors/pharmacology
  • Insulin/*pharmacology
  • Insulin Resistance
  • Isoquinolines/pharmacology
  • Tumor Necrosis Factor/pharmacology
  • Transcription Factors/genetics
  • Thiazoles/pharmacology
  • Non-U.S. Gov't
  • Support
  • Sphingosine/*analogs & derivatives/*pharmacology
  • Cytoplasmic and Nuclear/genetics
  • Receptors
  • Lipolysis/*drug effects
  • Mice
  • Chromans/pharmacology
  • Western
  • Blotting
  • Animal
  • 3'
  • 5'-Cyclic-Nucleotide Phosphodiesterase/analysis/*metabolism
  • 3T3 Cells
  • Adipocytes/*metabolism



Research group

  • Appetite Regulation
  • Insulin Signal Transduction
  • Molecular Endocrinology


  • ISSN: 1939-327X